olivLaw · European equity research
Ebusco Holding NV EBUS.AS
Netherlands · Euronext Amsterdam · ISIN NL0015002AG2 · Vertical: Listed companies from Netherlands
At the close of 06 Nov 2026, Ebusco Holding NV (EBUS.AS) stock was 0.13 EUR (−2.80% on the day), with market capitalisation 14.5 m EUR, beta 1.38, 52-week range 0.12–0.46 EUR.
Data as of · Source: ESEF annual reports and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 31.7
- weak (30–45)
- Bollinger (20, 2)
- 0.12 – 0.19
- in the lower half of the band · %B 0.01 · band width 41.2%
- SMA 50 / 200
- 0.18 / 0.27
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.02 / -0.01
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | EURO STOXX 50 | vs EURO STOXX 50 | Vertical median | |
|---|---|---|---|---|
| 1 month | −37.5% | −0.2% | −37.3 pp | — |
| 3 months | −52.3% | −5.4% | −46.9 pp | — |
| 6 months | −56.3% | +4.4% | −60.7 pp | — |
| Year to date | −69.1% | +6.5% | −75.5 pp | — |
| 1 year | −70.8% | +10.0% | −80.8 pp | +1.0% |
| 3 years | −99.7% | +48.6% | −148.2 pp | +5.5% |
| 5 years | −99.9% | +41.4% | −141.3 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 102.4 m | 10.7 m | 76.6 m |
| Revenue YoY | unavailable | −89.6% | +618.2% |
| Net income | -119.2 m | -200.6 m | -71.0 m |
| Net income YoY | unavailable | unavailable | unavailable |
| Diluted EPS | -10.06 | -10.79 | -0.61 |
| Diluted EPS YoY | unavailable | unavailable | unavailable |
| net % | -116.3% | -1,881.2% | -92.7% |
| Free cash flow | -118.8 m | -56.7 m | -28.1 m |
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 7.4 m EUR
- Financial debt
- 8.2 m EUR
- Net debt
- 726.0 k EUR
- Equity
- 3.3 m EUR
- Total assets
- 155.4 m EUR
- Debt / equity
- 2.48x
- Current ratio
- 0.94x
- ROE
- -461.0%
- ROA
- -42.3%
- FCF margin
- -36.6%
Financial statements (source on every figure)
Revenue and net income (EUR)
Margins
Income statement · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Revenue | 102.4 m | 10.7 m | 76.6 m | esef· 12 May 2026verified |
| Operating income | -103.9 m | -196.4 m | -64.6 m | esef· 12 May 2026verified |
| Depreciation & amortisation | 8.1 m | 11.1 m | 7.9 m | esef· 12 May 2026verified |
| EBITDA | -95.7 m ≈ | -185.3 m ≈ | -56.7 m ≈ | esef· 12 May 2026derived |
| Pre-tax income | -105.7 m | -200.6 m | -70.8 m | esef· 12 May 2026verified |
| Income tax | 14.5 m | 198.0 k | 130.0 k | esef· 12 May 2026verified |
| Net income | -119.2 m | -200.6 m | -71.0 m | esef· 12 May 2026verified |
| Diluted EPS | -10.06 | -10.79 | -0.61 | esef· 12 May 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Cash | 27.9 m | 2.4 m | 7.4 m | esef· 12 May 2026verified |
| Inventories | 106.5 m | 117.7 m | 80.6 m | esef· 12 May 2026verified |
| Current assets | 228.5 m | 137.0 m | 131.8 m | esef· 12 May 2026verified |
| Property, plant & equipment, net | 22.4 m | 11.7 m | 8.3 m | esef· 12 May 2026verified |
| Total assets | 319.8 m | 180.1 m | 155.4 m | esef· 12 May 2026verified |
| Short-term debt | — | 5.4 m | 8.2 m | esef· 12 May 2026verified |
| Current liabilities | 125.7 m | 131.1 m | 140.9 m | esef· 12 May 2026verified |
| Total liabilities | 141.5 m | 152.6 m | 152.1 m | esef· 12 May 2026verified |
| Equity | 178.3 m | 27.5 m | 3.3 m | esef· 12 May 2026verified |
| Shares outstanding at year end | 11.8 m | 18.6 m | 116.4 m | esef· 12 May 2026derived |
Cash flow · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Operating cash flow | -103.8 m | -53.7 m | -27.2 m | esef· 12 May 2026verified |
| Capex | 15.0 m | 3.0 m | 883.0 k | esef· 12 May 2026verified |
| Free cash flow | -118.8 m ≈ | -56.7 m ≈ | -28.1 m ≈ | esef· 12 May 2026derived |
| Investing cash flow | -20.1 m | -5.7 m | -911.0 k | esef· 12 May 2026verified |
| Financing cash flow | 56.6 m | 33.9 m | 33.2 m | esef· 12 May 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 29.2% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
06 Nov 2026Source: olivLaw, closing series
Market cap: 14.5 m EUR
Key indicators
Coverage and freshness
Score by group
29% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · the base of the ratio is not positive
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Assumptions (illustrative, editorial)
- Risk-free rate
- 3.0%
- Equity risk premium
- 5.5%
- Beta (default)
- 1.00
- Cost of equity
- 8.5%
- Terminal growth
- 2.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 29.2% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | -314.7% | 0 (vs peers) | 36% |
| Net margin · Quality | -92.7% | 6 (vs peers) | 21% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 0.9x | 11 (on a fixed band) | 14% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -192.9% | 0 (on a fixed band) | 29% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial11/100 · 1/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality2/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Ebusco Holding NV (EBUS.AS). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 76.6 m EUR in 2025; YoY growth 618.2%; net margin -92.7%; ROE -461.0%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 29.2% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
What contradicts it
- ROIC: -314.7%
- Net margin: -92.7%
- Current ratio: 0.9x
- FCF yield: -192.9%
Not assessed (insufficient data or a ratio without meaning): FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Listed companies from Netherlands · same country · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| ASML.ASASML Holding N.V. | 498.6 bn | 48.9 | 44.2% | 31.3% | +15.6% | +42% / +106% |
| DSFIR.ASDSM-Firmenich AG | 32.7 bn | 116.8 | 1.2% | 2.2% | +20.4% | +55% / +26% |
| ASM.ASASM International N.V. | 31.9 bn | 44.3 | 18.7% | 22.8% | +8.2% | +37% / +38% |
| AD.ASKoninklijke Ahold Delhaize N.V. | 30.9 bn | 13.7 | 15.3% | 2.5% | +3.4% | −4% / +29% |
| ADYEN.ASAdyen N.V. | 28.4 bn | 26.8 | 22.3% | 40.1% | +18.9% | −33% / −16% |
| HAL.ASHAL Trust | 15.3 bn | 9.6 | 10.5% | 12.8% | +1.2% | +21% / +46% |
| EXO.ASExor N.V. | 15.1 bn | — | -10.6% | — | −100.0% | +1% / −18% |
| BESI.ASBE Semiconductor Industries N.V. | 11.4 bn | 86.4 | 28.7% | 22.3% | −2.7% | +10% / +12% |
| AKZA.ASAkzo Nobel N.V. | 10.8 bn | 17.0 | 13.8% | 6.3% | −5.2% | +12% / −11% |
| AALB.ASAalberts N.V. | 4.4 bn | 24.8 | 7.2% | 5.7% | −5.3% | +45% / +11% |
| ARCAD.ASArcadis N.V. | 4.1 bn | 19.8 | 18.3% | 4.3% | −2.4% | +21% / +0% |
| BNJ.ASBanijay Group N.V. | 3.4 bn | 13.8 | 343.8% | 5.1% | +1.6% | −11% / −8% |
| BAMNB.ASKoninklijke BAM Groep N.V. | 3.3 bn | 42.0 | 9.1% | 1.3% | +2.9% | +47% / +403% |
| BFIT.ASBasic-Fit N.V. | 2.0 bn | 137.1 | 3.6% | 1.0% | +16.9% | +6% / +15% |
| HAVAS.ASHavas N.V. | 1.8 bn | 9.4 | 10.2% | 6.5% | +1.7% | +23% / unavailable |
| CRBN.ASCorbion N.V. | 1.6 bn | 8.3 | 27.3% | 14.9% | +1.9% | +39% / +55% |
| ECMPA.ASEurocommercial Properties N.V. | 1.4 bn | 11.2 | 5.9% | 45.4% | +4.2% | −4% / +19% |
| FUR.ASFugro N.V. | 963.7 m | — | -1.5% | -1.1% | −18.8% | −2% / −50% |
| ACOMO.ASAcomo N.V. | 681.5 m | 15.1 | 10.7% | 3.3% | +7.6% | −4% / +36% |
| FAST.ASFastned B.V. | 671.8 m | — | -28.2% | -21.7% | +66.1% | +62% / +26% |
| FFARM.ASForFarmers N.V. | 477.6 m | 9.6 | 14.5% | 1.6% | +14.8% | +21% / +122% |
| BRNL.ASBrunel International N.V. | 356.7 m | 116.8 | 1.0% | 0.3% | −10.8% | −12% / −34% |
| ALFEN.ASAlfen N.V. | 222.6 m | — | -0.1% | -0.0% | −10.7% | −3% / −78% |
| ENVI.ASEnvipco Holding N.V. | 219.9 m | — | -12.7% | -11.9% | −20.8% | −27% / +44% |
| CMCOM.ASCM.com N.V. | 192.5 m | — | -22.2% | -1.5% | −5.4% | +23% / −30% |
1- and 3-year price returns: for EBUS.AS from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (EUR)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
The qualitative analysis has not been written for this company yet.
Products, market & competition
The qualitative analysis has not been written for this company yet.
News & filings
In the press
No news in our archive over the last 180 days.
Annual reports (ESEF)
- Annual report 202512 May 2026
- Annual report 202407 May 2025
Figures computed by olivLaw from ESEF annual reports and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.